May 12, 2020
Pfizer to hold discussion at healthcare conference
Pfizer invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Pfizer
May 5, 2020
Pfizer, BioNTech in first doses in U.S. in global COVID-19 vaccine making
First participants have been dosed at NYU Grossman School of Medicine and University of Maryland School of Medicine.
April 28, 2020
Pfizer revenues 7% down, with $12 billion in Q1 2020
First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare(1), Revenues Declined 1% Operationally.
March 24, 2020
FDA OKs Pfizer’s SNDA for expanded indication of EUCRISA ointment, 2%, in children as young as 3 months of age with mild-to-moderate atopic dermatitis
EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of…
March 17, 2020
Pfizer, BioNTech enter clinical testing of COVID-19 prevention vaccine in April
Pfizer and BioNTech on Tuesday said they have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together on a potential mRNA-based coronavirus vaccine for preventing COVID-19 infection.
March 16, 2020
BioNTech, Fosun Pharma, Pfizer working on COVID-19 vaccine. Clinical testing in Germany in April
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
March 15, 2020
How do pharmaceutical companies profit from COVID-19? (do they?)
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
March 15, 2020
Pfizer’s five-point plan to battle COVID-19
Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic NEW YORK–(BUSINESS WIRE)–Pfizer today…
October 13, 2019
Pfizer’s abrocitinib met all endpoints in moderate to severe atopic dermatitis study
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.
September 27, 2019
Merck, Pfizer present avelumab’s activity in tumors treatment
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.